Anagram Therapeutics Series A · $20M raised · (2020)

Anagram Therapeutics is a clinical-stage private biopharmaceutical company focused on improving the lives of individuals suffering from exocrine pancreatic insufficiency (EPI) caused by conditions such as cystic fibrosis, pancreatic cancer, and other related disorders. The company is developing ANG003, an orally delivered recombinant enzyme therapy.